Physician profile
Phyu Phyu Soe
NPI 1376991943
$2,523.29
in general payments reported to CMS, 2019-2025
21 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $685 · 2023: $615 · 2024: $426 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.04 |
| Education | $142.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $681.38 | 2021-2025 | |
| Incyte Corporation | $336.24 | 2021-2023 | Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $309.15 | 2022-2024 | |
| Gilead Sciences, INC. | $299.79 | 2022-2024 | Trodelvy |
| Daiichi Sankyo INC. | $154.77 | 2021-2025 | Enhertu |
| Janssen Biotech, INC. | $146.99 | 2021-2022 | |
| Lilly USA, LLC | $108.96 | 2022-2024 | Jaypirca, Verzenio |
| Genzyme Corporation | $91.46 | 2022 | |
| Tactile Systems Technology INC | $70.53 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Genmab U.S., INC. | $58.35 | 2023-2025 | Epkinly |
| Sobi, INC | $38.25 | 2024 | |
| Merck Sharp & Dohme LLC | $34.32 | 2023 | Keytruda |
| Celgene Corporation | $24.76 | 2022 | |
| Pfizer INC. | $23.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.34 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $23.06 | 2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $22.49 | 2024 | Qinlock |
| Genentech USA, INC. | $20.22 | 2023 | |
| Glaxosmithkline, LLC. | $19.24 | 2025 | Jemperli, Zejula |
| Abbvie INC. | $18.62 | 2022 | |
| Stemline Therapeutics INC. | $17.89 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyu Phyu Soe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.